- Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
- Zai Lab Announces Participation in November Investor Conferences
- Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023
- Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China
- Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China
- Zai Lab Announces Participation in September Investor Conferences
- Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates
- Zai Lab to Announce Second Quarter 2023 Financial Results and Corporate Updates on August 7, 2023
- JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients
- Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
More ▼
Key statistics
On Thursday, Zai Lab Ltd (ZLAB:NMQ) closed at 16.02, 2.10% above its 52-week low of 15.69, set on Mar 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.43 |
---|---|
High | 16.43 |
Low | 15.96 |
Bid | 15.86 |
Offer | 16.16 |
Previous close | 16.19 |
Average volume | 702.10k |
---|---|
Shares outstanding | 99.21m |
Free float | 96.98m |
P/E (TTM) | -- |
Market cap | 1.59bn USD |
EPS (TTM) | -3.46 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 20:00 BST.
More ▼